Table II.

Correlation between clinicopathological characteristics and biochemical failure.

Characteristics	Hazard ratio	P-value	95% CI
Univariate analysis
Age	1.0954	0.0401	1.0039–1.2111
Preoperative PSA	1.0608	0.1041	0.9859–1.1196
cT1 vs. ≥cT2	3.5756	0.0157	1.2567–12.7632
pT2 vs. pT3	4.1182	0.0041	1.5666–11.9563
RP Gleason score ≤7 vs. ≥8	3.1470	0.0235	1.1760–8.2754
EPE0 vs. EPE1	4.4515	0.0025	1.6934–12.9237
RM0 vs. RM1	2.5284	0.1064	0.8023–6.8439
pN0 vs. pN1	14.4627	0.0097	2.2538–52.7430
PSA nadir (<0.008 vs. ≥0.008 ng/ml)	11.7402	<0.0001	4.2154–30.9738
Multivariate analysis
RP Gleason score ≤7 vs. ≥8	5.2407	0.0116	1.4613–19.6442
EPE0 vs. EPE1	3.1760	0.0216	1.1835–9.4170
pN0 vs. pN1	11.9323	0.0178	1.6884–55.7366
PSA nadir (<0.008 vs. ≥0.008 ng/ml)	26.3362	<0.0001	7.3445–104.6937

CI, confidence interval; PSA, prostate-specific antigen; RP, radical prostatectomy; EPE, extraprostatic extension; RM, resection margin.